ADAPTIMMUNE THERAPEUTICS PLC

• ⚠

  Material uncertainty over going concern

  The Directors have considered that material uncertainties exist that cast significant doubt upon the Group's ability to continue as a going concern for at least the next 12 months from the date of signing the financial statements.

• ◆

  9 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

1. ADAPTIMMUNE THERAPEUTICS PLC 2015-04-01 → present
2. ADAPTIMMUNE THERAPEUTICS LIMITED 2014-12-03 → 2015-04-01

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The Directors have considered that material uncertainties exist that cast significant doubt upon the Group's ability to continue as a going concern for at least the next 12 months from the date of signing the financial statements.”

Group structure

1. ADAPTIMMUNE THERAPEUTICS PLC · parent
   1. Adaptimmune Limited 100% · England and Wales · Biotechnology Research & Development
   2. Adaptimmune LLC 100% · United States of America · Biotechnology Research & Development and Commercial Sales
   3. Adaptimmune B.V. 100% · The Netherlands · Administrative
   4. CMI Intermediate Sub I, Inc. 100% · United States of America
   5. CMI Intermediate Sub II, Inc. 100% · United States of America
   6. TCR2 Therapeutics Inc. 100% · United States of America · Biotechnology Research & Development
   7. TRuC Therapeutics Limited 100% · England and Wales · Biotechnology Research & Development
   8. TRuC Securities Corporation(1) 100% · United States of America · Treasury

Significant events

• “On 24 March 2025, Adaptimmune Therapeutics plc (the "Company") entered into an amendment to the Loan and Security Agreement to prepay $25.0 million of the loan amount.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

1

last 24 months

Officers appointed

2

last 12 months

Officers resigned

9

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +195.3%

  £44,685,693 → £131,973,314

• Cash

  -36.7%

  £106,739,066 → £67,560,415

• Net assets

  -69.7%

  £31,894,737 → £9,663,454

• Employees

  +33.5%

  439 → 586

• Operating profit

  +50.8%

  -£116,163,084 → -£57,143,810

• Profit before tax

  +40.4%

  -£96,967,383 → -£57,761,305

• Wages

  +11.5%

  £49,012,602 → £54,651,594

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers